Navigation Links
Martek Announces Third Quarter 2007 Financial Results
Date:9/5/2007

e subject to quarter-to-quarter fluctuations, some of which may be significant. The forward-looking statements noted above are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors and cautionary statements set forth herein and in the Company's filings with the Securities and Exchange Commission, including, but not limited to, Part I, Item 1A of the Company's Form 10-K/A for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-Q, Form 10-Q/A and Form 8-K.

About Martek

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com.

CONTACT

Kyle Stults

Investor Relations

(410) 740-0081

kstults@martek.com

MARTEK BIOSCIENCES CORPORATION

Summary Consolidated Financial Information

(Unaudited - $ in thousands, except share and per share data)

Condensed Consolidated Statements of Income Data

Three months ended July 31, Nine months ended July 31,

2007 2006 2
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. PM announces a new health care order for India
2. PowderMed Announces Needle-Less Flu Vaccine
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
9. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ire/ -- Pamela Bowen, Chief Information Officer at...or the "Chief Innovation Officer" Appy Award for t...cloud computing. Appy Award recipients are nominat...RM or the Force.com platform in bringing new level...artner, service, support or IT organizations. ,...
(Date:12/4/2009)... cancers, particularly Ewing sarcomas and tumors o...tudy published online December 4 in the Journal o...as undertaken because there is limited research on...) for pediatric cancer patients. , Karen Wasilew...lood Disorders Service, Children,s Healthcare of A...
(Date:12/4/2009)... from the School of Medicine,s Department of Nutri...ch products of lipid peroxidation and some drugs o... The pathways were identified by a combination of ...dings shed new light on the mechanism of action of...wn as "the date rape drug." The manuscript publish...
(Date:12/4/2009)...phenomenon that was started by people that were lo...al work in the US, Canada, and other countries. In... have found that Mexican Dental Vacation is a grea... (PRWEB) December 4, 2009 -- Aft...n Dental Vacation is seeing their best year ever, ...
(Date:12/4/2009)...ators to crack down on abuse of opioid medications...The makers of 24 different prescription painkiller...s to curb the abuse of these opioid drugs. , T...re from U.S. Food and Drug Administration official...doses that occur with these medications each year,...
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
..., yet 2 million people die of cardiovascular disea...e is now affecting younger generations due to unhe...ture deaths. Recent studies have highlighted the ... to develop national strategies to combat heart di...
...M) has,focused its culinary expertise this time to...u salivating for more. Italians have known for cen...age as natural as spaghetti and,meatballs. Now Twi...ew., (Photo: http://www.newscom.com/cgi-bin/prnh...
...lutions, Inc.,(Accuro) (http://www.accurohealth.c...cle management market with the acquisition of TPMS...rovides contract management services to a,strong c...MS,personnel to continue to provide the excellent ...
... Hyperion,Therapeutics, Inc., a privately held bio...S. Zoth has been elected to the company,s Board of...e President and Chief,Financial Officer of MedImmu...n discussing her appointment, Ms. Zoth commented, ...
...ncrease the bronchoscopy market, to approximately...earch Group, WALT...,Research Group,s US Markets for ENT & Bronchoscop... to $180 million by 2012., To date, the majority ...
...ific Corporation (NYSE: BSX ) today announced the...ounsel. Pratt is a nationally known,attorney speci...ation. He,will hold the title of "Executive Vice P...cer Jim Tobin. He plans to join,the Company May 1s...
Other Medicine News:Health News:Joining efforts to tackle heart disease 2Health News:Joining efforts to tackle heart disease 3Health News:New Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free Connoisseurs 2Health News:Hyperion Therapeutics Elects Lota Zoth to Board of Directors 2Health News:Interventional Pulmonology Creeping into Bronchoscopy Market 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 3
(Date:12/4/2009)..., , BILLERICA, Mass., Dec. 4 /PRNewswi...y-owned subsidiary of Volcano Corporation (Nasdaq:...and successful testing of a novel integrated light...ves this proprietary optical engine design raises ... limitations of laser-based designs for swept sour...
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 /PRNewswire-First...r the "Company") (OTC Bulletin Board: NWBO) announ...has allowed its patent application on a system for...re of the Company,s DCVax® therapeutic cancer... key to the very high concentration of dendritic c...
(Date:12/3/2009)..., , ALISO VIEJO, Calif. and STATE COLLEG...SoftGenetics today announced the signing of an agr... services using SoftGenetics, NextGENe software fo... Ambry. ,, (Logo: http://www.newscom.com/cg...sheidt PhD, Ambry,s CSO said, "Our team at Ambry h...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 1Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 2Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 4Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 1Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 3Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 1Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 2Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 3
...s of Disease Activity as Measured,by MRI and Relap...ech, Inc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasda... II clinical study of Rituxan®,(rituximab) in ...is,(RRMS) were presented today at the American Aca...ituxan is a therapeutic antibody,that targets and ...
... reduced by 40 percent compared,to delayed treatme...lthCare,Pharmaceuticals announced today new data, ...on(R) (interferon beta-1b) treatment in,patients w... (MS),can significantly reduce the risk of permane...nded Disability Status Scale,(EDSS) by 40 percent(...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4
VascoTwist CC 9/60 M
VascoTwist E 9/60 S
VascoScrew E 8/60 M
VascoScrew CC 6/60 M
Medicine Products: